The Marcel van den Brink Lab
Immuno-oncology is increasingly becoming an important therapy for a variety of cancers. As Head of the Division of Hematologic Malignancies and an Attending Physician of the Adult Bone Marrow Transplantation Service, I see patients undergoing a bone marrow transplantation. In my lab, I study novel strategies to improve immune therapies for cancer patients with a special emphasis on the role of the intestinal microbiome in (patho)physiology and therapy, Chimeric Antigen Receptor T cell therapy, and regeneration of thymic function to improve T cell immunity.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 Mar 14. doi: 10.1038/s41591-022-01702-9. Epub ahead of print. PMID: 35288695.
Miltiadous O, Waters NR, Andrlova H, Dai A, Nguyen CL, Burgos da Silva M, Lindner S, Slingerland J, Giardina P, Clurman A, Armijo GK, Gomes AL, Lakkaraja M, Maslak PG, Scordo M, Shouval R, Staffas A, O’Reilly RJ, Taur Y, Prockop S, Boelens JJ, Giralt S, Perales MA, Devlin SM, Peled JU, Markey KA, van den Brink MRM. Early intestinal microbial features are associated with CD4 T cell recovery after allogeneic hematopoietic transplant. Blood. 2022 Jan 21:blood.2021014255. doi: 10.1182/blood.2021014255. Epub ahead of print. PMID: 35061893.
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, Shono Y, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I, Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 Feb 27;382(9):822-834. doi: 10.1056/NEJMoa1900623.
Markey KA, Schluter J, Gomes ALC, Littmann ER, Pickard AJ, Taylor BP, Giardina PA, Weber D, Dai A, Docampo MD, Armijo GK, Slingerland AE, Slingerland JB, Nichols KB, Brereton DG, Clurman AG, Ramos RJ, Rao A, Bush A, Bohannon L, Covington M, Lew MV, Rizzieri DA, Chao N, Maloy M, Cho C, Politikos I, Giralt S, Taur Y, Pamer EG, Holler E, Perales MA, Ponce DM, Devlin SM, Xavier J, Sung AD, Peled JU, Cross JR, van den Brink MRM. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020 Jul 2;136(1):130-136. doi: 10.1182/blood.2019003369.
Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C8, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T1, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM. Lactose Drives Enterococcus Expansion to Promote Graft-versus-Host Disease. Science. 2019; 366(6469)1143–1149.
Marcel R. M. van den Brink, MD, PhD
- Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation with a particular focus on intestinal microbiome and strategies to enhance thymus and immune reconstitution.
- MD, PhD, Universiteit Leiden
- Technische Universität München - Medical School, Ludwig-Maximilians-Universität München - Medical School Undergraduate
- University of Puerto Rico BS
- Vanderbilt University School of Medicine MD, PhD
- Memorial Sloan Kettering Cancer Center Radiation Oncology Residency
- Ludwigs-Maximilians-University, Munich, Germany
- Harvard Medical School, Boston, MA
- University of Cape Town, Capetown, SA.
- Hokkaido University Graduate School of Medicine, Sapporo, Japan
- Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Head of the Division of Hematologic Malignancies at MSKCC (2008 - present)
- Royal Dutch Academy of Sciences (2020)
- International Society for Experimental Hematology: Till and McCulloch Lectureship Award (2015)
- Alan N. Houghton Chair in Immunology at MSKCC (2007)
- Howard Hughes Physician Scientist Award (1996)
Lab News & Events
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Marcel R. M. van den Brink discloses the following relationships and financial interests:
MJH Life Sciences
Provision of Services
Ownership / Equity Interests; Provision of Services
Ownership / Equity Interests; Provision of Services (uncompensated)
Provision of Services
Rheos Medicines, Inc
Provision of Services
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Smart Immune SAS
Provision of Services (uncompensated)
WindMIL Therapeutics, Inc.
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.